Get All Information That You Search Here
Showing posts with label Germany. Show all posts
Showing posts with label Germany. Show all posts

Saturday, June 11, 2011

Germany: outbreak waning, but more deaths possible (AP)

HAMBURG, Germany – Germany's health minister says he's hopeful that the worst of an E. coli outbreak blamed on sprouts is over — but he is warning that the number of deaths, now at 33, may still increase.

Minister Daniel Bahr's comments came after health officials announced on Friday that they had traced the outbreak to sprouts from a farm in northern Germany. They also lifted a warning against eating cucumbers, tomatoes and lettuce, which initially had been suspected as possible culprits.

The E. coli outbreak, the world's deadliest, has sickened nearly 3,100 people — most of them in Germany — and prompted many in Europe to shun vegetables over recent weeks.

"The (E. coli) wave is gradually abating — there is reason to hope the worst is now over," Bahr was quoted Saturday as telling the Bild am Sonntag newspaper. He added that a major new flare-up is "very unlikely."

However, "further deaths are not ruled out, as painful as that is," he added.

In Hamburg, one of the areas worst hit by the outbreak, customers at the city's Wandsbek market were back to buying cucumbers, tomatoes and lettuce on Saturday.

With the end of the warning, "now they are coming back to the markets," said farmer Wolfgang Sannmann, who was selling vegetables and fruit. "And the consumer can buy again what he wants and what his appetite tells him."

Still, some customers remained wary despite officials' assurances that they had pinned down the source.

"I am still very cautious, because in the first place they said it's the cucumbers, and everyone stopped eating them, and now it's the sprouts," said real-estate agent Jessica Hemblen, 27. "I'm not sure whether this is it, or whether it's not going to be something different again."

"It can occur everywhere, and other things can come up too, so I am trying to get a good mixture (of vegetables) to lower the risk," said retiree Edith Karg.

Health officials say they tracked the bacteria's path from hospital patients struggling with diarrhea and kidney failure, to restaurants where they had dined, to specific meals and ingredients they ate, and finally back to a single farm.

Also on Friday, officials in Germany's North Rhine-Westphalia state said tests had found the deadly E. coli strain in a bag of sprouts from the farm that was in the garbage of a family near Cologne, two of whose members had been sickened.

They initially cautioned that the bag had been open for some time and more tests were under way. But Germany's federal risk assessment agency said Saturday that those tests confirmed the strain — adding to the certainty.

There are more questions to answer, including what contaminated the sprouts in the first place — perhaps tainted seeds or water, or nearby animals.

Interviews with thousands of patients, mostly women ages 20 to 50 with healthy lifestyles, led investigators to conclude initially that salads could be the problem. That resulting in the warning to avoid cucumbers, tomatoes and lettuce, which caused major losses for European farmers.

"Of course I have understanding for the companies that have been left sitting on their cucumbers, tomatoes and lettuces," said Bahr, the health minister.

"But I say that protecting health is the priority; if, thanks to the warning, a single human life was not endangered, that is in everyone's interest."

Germany joins France in suspending top Takeda drug (Reuters)

TOKYO/LONDON (Reuters) – Germany has joined France in suspending the use of Takeda Pharmaceutical's Actos diabetes drug, due to worries about a possible link to cancer.

The move is a blow for the Japanese firm, whose best-selling drug has worldwide sales of close to $5 billion, though the financial impact will be limited by the fact the drug faces looming generic competition in key markets.

Shares in Takeda fell 2.9 percent on Friday, against a 0.5 percent rise in the benchmark Nikkei average.

On Thursday, France's drug safety authority suspended use of both Actos and Competact -- which combines Actos and an older drug called metformin -- after an official French study found they appeared to slightly raise the risk of bladder cancer.

Germany's Federal Institute for Drugs and Medical Devices (BfArM) said it had decided to follow suit after receiving results of the study by France's national health insurance body, which tracked patients on diabetes drugs between 2006 and 2009.

"BfArM recommends the suspension of approval of pioglitazone (Actos) until further clarification. Doctors should not put new patients on pioglitazone," the German regulator said in a statement.

A Takeda spokesman had earlier said the German authorities had informed the company of their intentions.

Both the French and German regulators said patients currently being prescribed Actos should continue to take their medicines until they could consult with their doctors, since they could be in danger if they stopped treatment.

Other European countries are holding fire on Actos and a spokeswoman for the European Medicines Agency said it was not aware of any other national authorities taking action.

The European agency, based in London, initiated a review into the safety of Actos in March and its experts will discuss the latest data on the drug at a June 20-23 meeting.

Britain's drugs regulator said it was not recommending any changes to Actos use while the European review was going on and the Danish medicines agency also told Reuters it had no plans to "go it alone" on suspending the drug.

NO ACTION FROM FDA

In the United States, the FDA initiated a safety review of Actos last September, but Takeda said U.S. regulators had not signaled any intention to request a recall.

Japan's health ministry also said the body had no plans for a recall of the blockbuster product, which had global sales of 387.9 billion yen ($4.8 billion) in the year ended on March 31, accounting for 27 percent of Takeda's revenues.

Actos belongs to the same drug class as GlaxoSmithKline's Avandia, which was pulled from the market in Europe and had severe restrictions imposed on its use in the United States last September, after being linked to heart risks.

GSK's drug has not been associated with bladder cancer.

Actos was approved for use in Europe in 2000 but its potential bladder cancer risk, seen in tests of male rats, has long been a topic of discussion.

Interim results from trials being conducted by U.S. health insurer Kaiser Permanente, one of which began in 2003 and is slated to last 10 years, have so far not confirmed a clear association between Actos and bladder cancer.

(Additional reporting by Frank Siebelt in Frankfurt and Mette Fraende in Copenhagen; Editing by Chris Gallagher, Joseph Radford and Sophie Walker)